ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
15.70
-0.84 (-5.08%)
At close: Mar 5, 2026, 4:00 PM EST
15.85
+0.15 (0.96%)
After-hours: Mar 5, 2026, 7:51 PM EST
ADMA Biologics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 28.5, with a low estimate of 25 and a high estimate of 32. The average target predicts an increase of 81.53% from the current stock price of 15.70.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 8, 2025.
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Maintains $25 → $32 | Strong Buy | Maintains | $25 → $32 | +103.82% | May 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +59.24% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +65.61% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +59.24% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +14.65% | Oct 14, 2024 |
Financial Forecast
Revenue This Year
646.43M
from 510.17M
Increased by 26.71%
Revenue Next Year
787.24M
from 646.43M
Increased by 21.78%
EPS This Year
0.91
from 0.60
Increased by 52.15%
EPS Next Year
1.19
from 0.91
Increased by 30.73%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 666.8M | 813.8M | |||
| Avg | 646.4M | 787.2M | |||
| Low | 619.9M | 753.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 30.7% | 25.9% | |||
| Avg | 26.7% | 21.8% | |||
| Low | 21.5% | 16.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.99 | 1.32 | |||
| Avg | 0.91 | 1.19 | |||
| Low | 0.83 | 1.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 64.5% | 44.9% | |||
| Avg | 52.2% | 30.7% | |||
| Low | 38.8% | 18.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.